Related Stories Oral semaglutide reduces heavy drinking in adults with alcohol use disorder Popular diabetes drugs do not alter the risk of developing a blinding eye condition Trial successfully lowers alcohol use in humanitarian setting Semaglutide recipients experienced greater reductions in the number of heavy drinking days, specifically 41.1 percentage points, compared with placebo recipients (26.4), corresponding to a moderate effect size
Frequently studied in diabetic-ulcer contexts
Competitive Landscape Beyond semaglutide products, Health Canada continues to review other GLP-1 medications including Eli Lilly's Mounjaro for additional indications
ReadyRx GLP-1 holds a strong overall rating across verified review platforms, with an average of 4.7 out of 5 stars based on several hundred user submissions
Wegovy and Its Safety Profile: What You Should Know Wegovy carries an FDA boxed warning regarding the risk of thyroid C-cell tumors based on rodent studies
Debido a las variaciones naturales en las propiedades de los ingredientes activos, el color, el sabor y el olor del producto pueden variar ligeramente de un lote a otro